Thursday 02 February 2017

12:00 - 13:30  Arrival / Registration with light refreshments
ATC Reception and Foyer

13:30 - 13:45  Opening remarks
ATC Auditorium

13:45 - 17:30  Session 1: Unleashing endogenous immunity
ATC Auditorium

13:45 - 14:15  To be presented onsite
Ugur Sahin
Johannes Gutenberg University Mainz, Germany

14:15 - 14:30  Heterogeneity and dynamics of the tumor-infiltrating lymphocyte repertoire
Isabel Poschke
German Cancer Research Center, Germany

14:30 - 14:45  NOX2-derived oxidative stress promotes melanoma metastasis by inhibiting IFN-gamma producing NK cells
Ebru Aydin
Gothenburg University, Sweden

14:45 - 15:15  Coffee break kindly sponsored by Roche
ATC Foyer

15:15 - 15:45  T cell differentiation in chronic infection
Dietmar Zehn
Technical University of Munich, Germany

15:45 - 16:15  Targeting the driver mutation IDH1R132H in brain tumors
Michael Platten
German Cancer Research Center, Germany

16:15 - 17:00  Coffee break (kindly sponsored by Roche) & Meet the speakers
ATC Foyer
17:00 - 17:30  What do T cells recognize on tumor cells?  
John Haanen  
*Netherlands Cancer Institute, The Netherlands*

17:30 - 17:45  Flash talks (1 slide / 2 min each) in ATC Auditorium:  
Kroon #51, Thiesen #61, Veerman #63, Volkmar #65, Younos #67

17:45 - 19:00  Poster Session I (odd numbers)  
ATC Foyer

19:00 - 20:30  Welcome reception with band and light refreshments  
ATC Foyer

Page 4
Friday 03 February 2017

09:00 - 12:00  Session 2: Clinical studies of T cell-based immunotherapies
   ATC Auditorium

09:00 - 09:30  T Cell-engaging Antibodies for Cancer Therapy
   Patrick Baeuerle
   *MPM Capital, United States of America*

09:30 - 09:45  High mutational load drives durable remission by targeting programmed death receptor 1 in a patient with metastatic luminal breast cancer
   Carlo Fremd
   *National Center for Tumor Diseases, Germany*

09:45 - 10:15  What do we need for Successful Adoptive Immunotherapy of Solid Tumors?
   Malcolm Brenner
   *Baylor College of Medicine, United States of America*

10:15 - 10:45  Coffee break *kindly sponsored by Roche*
   ATC Foyer

10:45 - 11:15  Immune Checkpoint Blockade in treatment of advanced Melanoma
   Dirk Schadendorf
   *University Hospital Essen, Germany*

11:15 - 11:45  CRISPR/Cas9-targeted chimeric antigen receptor enhances CAR T cell-mediated tumor eradication
   Michel Sadelain
   *Memorial Sloan Kettering Cancer Center, United States of America*

11:45 - 12:00  Immune evasion and PD-1-positive T cell infiltration in DNA mismatch repair-deficient colorectal cancer
   Matthias Kloor
   *University Hospital Heidelberg, Germany*
12:00 - 13:45  Lunch  
ATC Foyer

13:45 - 17:30  Session 3: Markers of effective immune responses  
ATC Auditorium

13:45 - 14:15  TCR gene editing of memory stem T cells for cancer  
Chiara Bonini  
San Raffaele Scientific Institute, Italy

14:15 - 14:45  To be presented onsite  
Jérôme Galon  
INSERM, France

14:45 - 15:00  AT1413: an antibody isolated from a cured Acute Myeloid Leukemia (AML) patient that is highly efficacious against AML in vivo  
Greta de Jong  
Academic Medical Center / AIMM Therapeutics, The Netherlands

15:00 - 15:30  Genomic analysis of human tumor immunity  
Nir Hacohen  
Massachusetts General Hospital / Harvard Medical School, United States of America

15:30 - 16:15  Coffee break (kindly sponsored by Roche) & Meet the speakers  
ATC Foyer

16:15 - 16:30  Investigation of tumor-reactive T-cell repertoire in the immune infiltrate of metastatic melanoma under immune checkpoint inhibition  
Jessica Hassel  
University Hospital Heidelberg, Germany

16:30 - 16:45  Immunotherapy for melanoma patients: towards identification of predictive response biomarkers  
Michal Harel  
Tel Aviv University, Israel
16:45 - 17:00  AML patients cured after allogeneic hematopoietic stem cell transplantation develop antibodies capable of directly killing AML blasts in vitro and in vivo

Gemma Moiset
Academic Medical Centre / AIMM Therapeutics, The Netherlands

17:00 - 17:30  Modulating T cell metabolism for cancer immunotherapy
Roger Geiger
Institute for Research in Biomedicine, Switzerland

17:30 - 17:45  Flash talks (1 slide / 2 min each) in ATC Auditorium:
Kather #48, Krall #50, Schneidt #58, Tunali #62

17:45 - 19:00  Poster Session II (even numbers)
ATC Foyer

19:00 - 21:00  Banquet Dinner
ATC Canteen

21:00 - 00:00  Conference Party
ATC Rooftop Lounge
### Saturday 04 February 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 4: Inducing Immunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 12:15</td>
<td>ATC Auditorium</td>
</tr>
</tbody>
</table>

#### 09:00 - 09:30
**T cell therapies for Hematologic Cancers – Beyond CARs**  
Catherine Bollard  
*Children’s National Medical Center / George Washington University, United States of America*

#### 09:30 - 09:45
**Oncolytic Measles Virus for Tumor-Specific Vaccination**  
Christine Engeland  
*National Center for Tumor Diseases, Germany*

#### 09:45 - 10:00
**Development of rational immunomodulation strategies for virotherapy**  
Ruta Veinalde  
*National Center for Tumor Diseases, Germany*

#### 10:00 - 10:30
**Adoptive T cell therapy**  
Thomas Blankenstein  
*Max-Delbrück-Center for Molecular Medicine, Germany*

#### 10:30 - 11:00
Coffee break *(kindly sponsored by Roche)* & Meet the speakers  
ATC Foyer

#### 11:00 - 11:15
**BITE-armed oncolytic measles viruses for cancer immunovirotherapy**  
Johannes Heidbuechel  
*National Center for Tumor Diseases, DKFZ, Germany*

#### 11:15 - 11:30
**The molecular basis of CD4+ T-cell help for the cytotoxic T-cell response against cancer**  
Tomasz Ahrends  
*Netherlands Cancer Institute, The Netherlands*

#### 11:30 - 11:45
**Direct detection of predicted tumor neopeitopes by targeted mass spectrometry**  
Angelika Riemer  
*German Cancer Research Center, Germany*
Programme

11:45 - 12:15  Crosstalk between the adaptive and innate immune system in metastatic breast cancer
Karin de Visser
The Netherlands Cancer Institute, The Netherlands

12:15 - 14:00  Lunch
ATC Canteen

14:00 - 17:00  Session 5: Targeting the microenvironment
ATC Auditorium

14:00 - 14:30  Anti-tumor T cells- you are what you eat
Susan Kaech
Yale University, United States of America

14:30 - 15:00  The mechanistic basis of cancer immunotherapy
Ira Mellman
Genentech, United States of America

15:00 - 15:15  Myeloid Derived Suppressor Cells-Mast Cells Cross-Talk Via C40-CD40L Mediate Tumor Specific Immunosuppression in Prostate Cancer
Elena Jachetti
Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

15:15 - 15:30  Hypoxia induces a new population of tumor-reactive CD8 T cells expressing high levels of PD-1 and IL-10
Telma Lanca
The Netherlands Cancer Institute, The Netherlands

15:30 - 16:00  Coffee break *kindly sponsored by Roche*
ATC Foyer

16:00 - 16:30  Inflammation-induced phenotypic plasticity of tumor and immune cells in disease progression and therapy resistance of melanoma
Thomas Tüting
University of Magdeburg, Germany
16:30 - 16:45  Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
   Bjoern Wendik
   PerkinElmer, Germany

16:45 - 17:00  The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
   Jana K. Sonner
   German Cancer Research Center, Germany

17:00 - 17:15  Closing remarks
   ATC Auditorium